These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33469693)

  • 21. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiomics strategy for glioma grading using texture features from multiparametric MRI.
    Tian Q; Yan LF; Zhang X; Zhang X; Hu YC; Han Y; Liu ZC; Nan HY; Sun Q; Sun YZ; Yang Y; Yu Y; Zhang J; Hu B; Xiao G; Chen P; Tian S; Xu J; Wang W; Cui GB
    J Magn Reson Imaging; 2018 Dec; 48(6):1518-1528. PubMed ID: 29573085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of Gliomas.
    Arevalo-Perez J; Peck KK; Young RJ; Holodny AI; Karimi S; Lyo JK
    J Neuroimaging; 2015; 25(5):792-8. PubMed ID: 25867683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas.
    Schebesch KM; Brawanski A; Doenitz C; Rosengarth K; Proescholdt M; Riemenschneider MJ; Grosse J; Hellwig D; Höhne J
    Clin Neurol Neurosurg; 2018 Sep; 172():177-182. PubMed ID: 30032095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning.
    Lee J; Wang N; Turk S; Mohammed S; Lobo R; Kim J; Liao E; Camelo-Piragua S; Kim M; Junck L; Bapuraj J; Srinivasan A; Rao A
    Sci Rep; 2020 Nov; 10(1):20331. PubMed ID: 33230285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
    Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
    Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.
    Saini J; Gupta PK; Sahoo P; Singh A; Patir R; Ahlawat S; Beniwal M; Thennarasu K; Santosh V; Gupta RK
    Neuroradiology; 2018 Jan; 60(1):43-50. PubMed ID: 29090331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative analysis of permeability for glioma grading using dynamic contrast-enhanced magnetic resonance imaging.
    Zhao M; Guo LL; Huang N; Wu Q; Zhou L; Zhao H; Zhang J; Fu K
    Oncol Lett; 2017 Nov; 14(5):5418-5426. PubMed ID: 29113174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging biomarker analysis of advanced multiparametric MRI for glioma grading.
    Vamvakas A; Williams SC; Theodorou K; Kapsalaki E; Fountas K; Kappas C; Vassiou K; Tsougos I
    Phys Med; 2019 Apr; 60():188-198. PubMed ID: 30910431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas.
    Conte GM; Altabella L; Castellano A; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Caulo M; Falini A; Anzalone N
    Eur Radiol; 2019 Jul; 29(7):3467-3479. PubMed ID: 30972545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiomics Analysis for Glioma Malignancy Evaluation Using Diffusion Kurtosis and Tensor Imaging.
    Takahashi S; Takahashi W; Tanaka S; Haga A; Nakamoto T; Suzuki Y; Mukasa A; Takayanagi S; Kitagawa Y; Hana T; Nejo T; Nomura M; Nakagawa K; Saito N
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):784-791. PubMed ID: 31344432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Evaluation of Radiomic Models in Distinguishing Pilocytic Astrocytoma From Cystic Oligodendroglioma With Multiparametric MRI.
    Zhao Y; Lu Y; Li X; Zheng Y; Yin B
    J Comput Assist Tomogr; 2020; 44(6):969-976. PubMed ID: 32976261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging.
    Yoon HJ; Ahn KJ; Lee S; Jang JH; Choi HS; Jung SL; Kim BS; Jeun SS; Hong YK
    Neuroradiology; 2017 Jul; 59(7):665-675. PubMed ID: 28550465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Hata N; Mizoguchi M; Yamamoto H; Iwaki T; Hiwatashi A; Ishigami K
    Sci Rep; 2022 Jun; 12(1):9197. PubMed ID: 35654812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.
    Shinozaki N; Uchino Y; Yoshikawa K; Matsutani T; Hasegawa A; Saeki N; Iwadate Y
    J Neurosurg; 2011 Jun; 114(6):1640-7. PubMed ID: 21214332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
    Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
    Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of perfusion- and diffusion-weighted imaging to differentiate between pilocytic astrocytomas and high-grade gliomas: a multicenter study in Japan.
    Kikuchi K; Hiwatashi A; Togao O; Yamashita K; Kamei R; Kitajima M; Kanoto M; Takahashi H; Uchiyama Y; Harada M; Shinohara Y; Yoshiura T; Wakata Y; Honda H
    Neuroradiology; 2018 Apr; 60(4):391-401. PubMed ID: 29450601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies].
    Daumas-Duport C; Koziak M; Miquel C; Nataf F; Jouvet A; Varlet P
    Neurochirurgie; 2005 Sep; 51(3-4 Pt 2):247-53. PubMed ID: 16292168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors.
    Narang J; Jain R; Scarpace L; Saksena S; Schultz LR; Rock JP; Rosenblum M; Patel SC; Mikkelsen T
    J Neurooncol; 2011 Apr; 102(2):287-93. PubMed ID: 20680399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.